Related Experiment Video
Updated: May 8, 2026

Ameliorating Osteoarthritis in Mice Using Silver Nanoparticles
Published on: June 2, 2023
Chondroitin and glucosamine in the management of osteoarthritis: an update
Yves Henrotin1, Cécile Lambert
1Bone and Cartilage Research Unit, Institute of Pathology, Level 5, CHU Sart-Tilman, University of Liège, 4000, Liège, Belgium. yhenrotin@ulg.ac.be
Abstract:
The objective of osteoarthritis (OA) treatment is not only control of symptoms (i.e. reducing pain and improving function) but also to preserve joint structure and maintain quality of life. OA management remains challenging. Glucosamine and chondroitin are two compounds available for treatment of OA patients. Taken alone or in combination, they have a good safety profile and a variety of effects. In-vitro and in-vivo experiments have revealed that both compounds induced key intermediates in the OA pathophysiological process. Clinical trials, although providing conflicting and questionable results, report symptomatic and structure-modifying effects for both pharmaceutical-grade compounds. This review will discuss all these subjects and emphasize the importance of the quality of tested compounds for achieving high quality clinical trials.
Related Concept Videos
Rheumatic Heart Disease III: Medical Management
Atherosclerosis III: Management
Glycosaminoglycans
GAGS are found in the extracellular matrix of vertebrates, invertebrates, and bacteria. Due to their polar nature they attract water, and serve as excellent lubricants or shock absorbers in an animal body.
Hyaluronic...
Chronic Obstructive Pulmonary Disease-V: Management
Smoking Cessation
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...